PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00300677
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Belmont, Massachusetts, United States
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 119
- Registration Number
- NCT00299494
- Locations
- ๐บ๐ธ
Emory University Hospital, Atlanta, Georgia, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธNorthwestern Medical Faculty Foundation, Chicago, Illinois, United States
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
Completed
- Conditions
- Arthritis, PsoriaticPsoriasisSkin Diseases, Papulosquamous
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT00293709
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Muenchen, Germany
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
Completed
- Conditions
- Arthritis, PsoriaticPsoriasisSkin Diseases, Papulosquamous
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1308
- Registration Number
- NCT00293722
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Toerwang-Samerberg, Germany
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00291577
- Locations
- ๐ธ๐ช
Pfizer Investigational Site, Stockholm, Sweden
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Phase 3
Completed
- Conditions
- Antifungal Prophylaxis of Invasive Fungal Infections
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 489
- Registration Number
- NCT00289991
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Manchester, United Kingdom
[S,S]-Reboxetine Dose-Range Finding Trial
Phase 2
Completed
- Conditions
- Pain
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 280
- Registration Number
- NCT00288652
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Tacoma, Washington, United States
A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections
Phase 4
Completed
- Conditions
- Invasive Fungal Infections
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT00288197
- Locations
- ๐จ๐ณ
Pfizer Investigational Site, Tianjin, China
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: PF-04494700 (TTP488)Other: Placebo
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00287183
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
Phase 3
Terminated
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00287066
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath